MANAGERS’ TRANSACTIONS
____________________________________________
Person subject to the notification requirement
Position: Member of the Board/Deputy member
Issuer:
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 61609/5/4
____________________________________________
Transaction date: 2024-05-03
Outside a trading venue
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE
Transaction details
(1): Volume: 1112 Unit price:
Aggregated transactions (1):
Volume: 1112 Volume weighted average price:
President and CEO | SVP, Corporate Functions |
Publisher:
Communications
Orionintie 1A, FI-02200
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to
© OMX, source